Patent application number | Description | Published |
20100028449 | FERMENTED MILK PRODUCT AND USE THEREOF - The present invention relates to an oral formulation comprising a microcapsule containing bacteria and a fermented milk carrier. There is also provided a method of medical treatment of an inflammatory gastrointestinal disease or disorder in a subject in need thereof, comprising detecting the presence of inflammatory gastrointestinal disease or disorder in the subject, wherein if inflammatory gastrointestinal disease or disorder is detected, then administering the formulation of the present invention to the subject. | 02-04-2010 |
20100047320 | ORAL POLYMERIC MEMBRANE FERULOYL ESTERASE PRODUCING BACTERIA FORMULATION - The present invention relates to an oral formulation to lower serum or hepatic lipid and triglyceride concentrations, hepatic inflammation and/or insulin resistance in a patient comprising live feruloyl esterase producing microorganisms alone or in association with a pharmaceutically acceptable carrier resistant to gastric conditions, and wherein the microorganisms are wild type, genetically modified, or combination thereof. The present invention is also directed to an oral formulation to lower serum or hepatic lipid and triglyceride concentrations, hepatic inflammation and/or insulin resistance in a patient, which comprises polymeric microcapsules containing live feruloyl esterase producing microorganisms in suspension in a pharmaceutically acceptable carrier, wherein said microcapsules are semipermeable and resistant to gastro-intestinal conditions, and wherein said microorganism are wild type, genetically modified, or combination thereof as well as methods of preventing or improving liver diseases and disorders and uses thereof. | 02-25-2010 |
20100074933 | Cell And Enzyme Compositions For Modulating Bile Acids, Cholesterol and Triglycerides - The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a biologically active agent which decreases the amount of the target compound; b) a retainer for retaining the biologically active agent by contacting the agent to limit movement of the agent; and c) a carrier. | 03-25-2010 |
20100215724 | Microcapsule Nanotube Devices for Targeted Delivery of Therapeutic Molecules - A nanotube device comprises a gel matrix that includes microcapsules and functionalized nanotubes, or other functionalized nanostructures incorporated into said gel matrix. Pharmaceutical compositions and methods of treatment comprising same. The pharmaceutical compositions of the present invention enable the specific and targeted delivery of therapeutic agents such as DNA molecules, peptides, including antibodies, drug molecules (e.g. small organic molecules), while offering sufficient resistance towards mucus layer of the intestine and high concentrations of enzymes and other molecules found in the blood stream and the GI tract. | 08-26-2010 |
20110104240 | Nitric Oxide Device and Method for Wound Healing, Treatment of Dermatological Disorders and Microbial Infections - The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides methods and uses for treating wounds, microbial infections and dermatological disorders and for preserving meat products. | 05-05-2011 |
20110106000 | Nitric Oxide Compositions and Devices and Methods for Cosmesis - The present disclosure provides a device having a casing with a barrier surface and a contact surface and a composition in the casing having a nitric oxide precursor and an isolated enzyme or live cell expressing an endogenous enzyme, for converting the nitric oxide gas precursor to nitric oxide gas or having activity on a substrate that produces a catalyst that causes the conversion of the nitric oxide gas precursor to nitric oxide gas. The present disclosure also provides compositions, methods and uses for skin cosmesis. | 05-05-2011 |
20110217368 | BACTERIAL COMPOSITIONS FOR PROPHYLAXIS AND TREATMENT OF DEGENERATIVE DISEASE - The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 μmol glycodeoxycholic acid (GDCA)/gram/hour and >2 μmol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 μmol GDCA/g/hr and >7 μmol TDCA/g/hr when measured over 30 minutes. | 09-08-2011 |
20130337067 | NON-VIRAL NANOPARTICLE-BASED DELIVERY SYSTEM - The present invention concerns a polymeric material for the production of a non-viral nanoparticle. The polymeric material comprises (i) a hydrophilic linear polymer having a first end and a second end, (iii) a cross-linkable cationic polymer covalently bonded to the first end of the hydrophilic linear polymer, and (iii) at least one targeting/penetrating peptide covalently associated to the second end of the hydrophilic linear polymer. Also disclosed herein are nanoparticles produced with these polymeric material, processes for making the polymeric material and the nanoparticles as well as use of the nanoparticles. | 12-19-2013 |
20140316323 | DEVICE, USE THEREOF AND METHOD FOR REDUCING SCARRING OF WOUND - A scar reducing device for stretching skin having a closed wound therein is provided. The device is for reducing scar formation. The device comprises first and second fasteners removably attachable to skin regions located proximate to the wound. The device also comprises an extension mechanism cooperating with said first and second fasteners. The extension mechanism is movable between contracted and extended configurations. When the fasteners are affixed to the skin, the mechanism forces the first and second fasteners away from one another with a predetermined tensile force, stretching the skin proximate to the wound. Use of the device is also provided, along with a method for reducing scarring of a closed wound. | 10-23-2014 |